Trial Profile
A multicenter, double-blind, randomized study to evaluate the safety and efficacy of the addition of sitagliptin to patients with type 2 diabetes mellitus who have inadequate glycemic control on metformin therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 01 Feb 2014 Results published in the Drugs and Aging.
- 01 Feb 2008 Primary endpoint results have been published
- 21 Oct 2006 New trial record.